Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01435 | N-Ac-Cys-MC-VC-PAB-MMAE | 1628933-80-1 |
| N-Ac-Cys-MC-VC-PAB-MMAE is an ADC metabolite used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 |
| mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate. | Inquiry | |
| BADC-01449 | Pomalidomide-PEG3-CO2H | 2138440-82-9 |
| Pomalidomide-PEG3-C2-carboxylic acid is a PROTAC block consist of Pomalidomide linked to PEG with a carboxylic acid functional group for conjugation reactions. | Inquiry | |
| BADC-01450 | MCC-DM1 | 1100692-14-5 |
| MCC-DM1 is a drug-linker conjugate for ADC synthesis, such as Anti-CD22-MCC-DM1. | Inquiry | |
| BADC-01451 | MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT | 2378428-19-2 |
| MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT, a camptothecin-linker compound, is part of a drug-linker conjugate for ADC. For details, please refer to Example 4-1 in patent document WO2019195665A1. | Inquiry | |
| BADC-01452 | MC-SN38 | 1473403-87-0 |
| MC-SN38 is a highly efficacious antineoplastic compound utilized within the realm of biomedicine and emerges as a derivative hailing from the natural entity SN-38. Distinguished by its formidable cytotoxic potential against malignant cells, MC-SN38 finds widespread application in combating an assortment of solid neoplasms encompassing colorectal, gastric, and pancreatic origins. | Inquiry | |
| BADC-01453 | Thalidomide-NH-PEG7 | 2641838-98-2 |
| Thalidomide-NH-PEG7 is an E3 ligase ligand-linker conjugate used in the synthesis of ADCs. Thalidomide-NH-PEG7 can be linked to protein ligands through a linker to form PROTAC iRucaparib-AP6 (a highly specific PARP1 degrader). | Inquiry | |
| BADC-01454 | 2',3'-cGAMP-C2-PPA | 2586047-11-0 |
| 2',3'-cGAMP-C2-PPA (45), a cyclic dinucleotide, is a STING agonist (US20210015941A1). 2',3'-cGAMP-C2-PPA is a part of antibody-linker conjugate for ADC (drug-linker conjugate for ADC), which can be used to synthesize antibody conjugates for targeted cancer research. | Inquiry | |
| BADC-01455 | Modified MMAF-C5-COOH | 1404071-65-3 |
| Modified MMAF-C5-COOH is a drug-linker conjugate for ADC. | Inquiry | |
| BADC-01457 | CCK2R Ligand-Linker Conjugates 1 | 1452145-13-9 |
| CCK2R Ligand-Linker Conjugates 1 are ligand-linker conjugates that bind to the cytotoxic microtubule inhibitors Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. | Inquiry | |
| BADC-01458 | SuO-Val-Cit-PAB-MMAE | |
| SuO-Val-Cit-PAB-MMAE is part of an antibody drug conjugate (drug-linker conjugate for ADC). Consists of the peptide SuO-Val-Cit-PAB linked to the antimitotic agent MMAE, a tubulin inhibitor. | Inquiry | |
| BADC-01459 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 |
| MC-betaglucuronide-MMAE-1 is part of an antibody-drug conjugate consisting of tubulin polymerization inhibitor MMAE and degradable ADC linker MC-betaglucuronide. | Inquiry | |
| BADC-01460 | DBM-MMAF | 1810001-93-4 |
| DBM-MMAF is composed of linker DBM and toxic molecule MMAF, which can be used to prepare antibody-conjugated drugs. | Inquiry | |
| BADC-01461 | MC-betaglucuronide-MMAE-2 | |
| MC-betaglucuronide-MMAE-2 is part of an antibody-drug conjugate consisting of tubulin polymerization inhibitor MMAE and degradable ADC linker MC-betaglucuronide. | Inquiry | |
| BADC-01462 | N3-PEG4-DYKDDDD-Doxorubicin | |
| N3-PEG4-DYKDDDD-Doxorubicin is part of an antibody drug conjugate consisting of the anthracycline antibiotic Doxorubicin and a degradable ADC linker N3-PEG4-DYKDDDD. | Inquiry | |
| BADC-01463 | Azide-PEG4-VC-PAB-Doxorubicin | |
| Azide-PEG4-VC-PAB-Doxorubicin is composed of linker Azide-PEG4-VC-PAB and toxic molecule Doxorubicin, which can be used to prepare antibody-conjugated drugs. | Inquiry | |
| BADC-01464 | N3-PEG4-YPYDVPDYA-Doxorubicin | |
| N3-PEG4-YPYDVPDYA-Doxorubicin is part of an antibody drug conjugate consisting of the anthracycline antibiotic Doxorubicin and the degradable ADC linker N3-PEG4-YPYDVPDYA. | Inquiry | |
| BADC-01465 | MB-VC-MGBA | 932744-62-2 |
| MB-VC-MGBA is a part of antibody drug conjugates, which is formed by linking DNA alkylating agent MGBA and ADC linker MB-VC. | Inquiry | |
| BADC-01466 | Desmethyl Vc-seco-DUBA | |
| Desmethyl Vc-seco-DUBA is an innovative biomedical product used in the treatment of various diseases. It exhibits potent anti-inflammatory properties, making it effective in managing chronic inflammation associated with autoimmune disorders. Its precise mechanism of action involves specifically targeting the overactive immune response and modulating inflammatory pathways. By alleviating inflammation, Desmethyl Vc-seco-DUBA offers promising therapeutic potential in conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. | Inquiry | |
| BADC-01467 | Lys-Nε-SPDB-DM4 | 1280215-91-9 |
| Lys-Nε-SPDB-DM4 is a drug-linker conjugate consisting of the potent tubulin inhibitor DM4 and the linker Lys-Nε-SPDB for the preparation of antibody-drug conjugates (ADCs). | Inquiry |
